메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Cenra Healthcare and Dr. Reddy's Strengthen Strategic Partn…

TAIPEI, July 21, 2025 -- Cenra Healthcare, the sales and marketing arm of Cenra Inc. (TWSE: 3716), today announced the deepening of its long-standing collaboration with the global pharmaceutical company Dr. Reddy's Laboratories (Taiwan) Ltd (Dr. Reddy's). Since the partnership began in 2020, the two companies have worked closely to introduce a diverse range of high-quality generic drugs and innovative formulations to patients in Taiwan, with a shared commitment to broadening access to affordable and clinically valuable treatments. "We are proud to strengthen our collaborat
- 김갑성 기자
- 2025-07-21 19:35
CPHI & PMEC Shenzhen 2025: Unlocking New Opportunities in A…

SHANGHAI, July 21, 2025 -- CPHI & PMEC China 2025 concluded in June with a record-breaking 109,056 attendees, underscoring strong demand within China's thriving pharma industry. Building on this success, CPHI & PMEC Shenzhen 2025 will take place from 1–3 September 2025 at Shenzhen Convention & Exhibition Center (SZCEC), addressing the growing demand for access to South China's key pharma markets. As a key gateway to the Guangdong-Hong Kong-Macau Greater Bay Area, Shenzhen is positioned to drive pharma innovation. The region's health industry GDP is projected
- 김갑성 기자
- 2025-07-21 14:31
CorestemChemon Expands Global CRO Reach with ATG Lifete…

[ 메디채널 김갑성 기자 ] Strategic partnership to deliver transcriptomics-powered, organoid-based preclinical testing for high-impact drug discovery SEOUL, South Korea, July 21, 2025 -- CorestemChemon, a leading GLP-certified preclinical CRO based in South Korea, has entered into a strategic partnership with ATG Lifetech, a biotechnology company specializing in transcriptome analytics and organoid-based modeling. This collaboration aims to deliver next-generation, precision-driven non-clinical solutions to pharmaceutical companies and biotech ventures across the U.S., Europe, and Asia.
- 김갑성 기자
- 2025-07-21 10:54
Texas Cardiac Arrhythmia Institute at St. David's Medical Cente…

AUSTIN, Texas, July 21, 2025 -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first in the nation to implant an FDA-approved novel leadless system that provides cardiac resynchronization therapy to patients with heart failure. Cardiac resynchronization therapy improves the timing of the heart's contractions, helping to restore the normal rhythm of the heartbeat. The first procedure was recently performed by Robert Canby, M.D., cardiac electrophysiologist at TCAI. "This technology marks a significant advancem
- 김갑성 기자
- 2025-07-21 08:47
세인트 데이비드 메디컬 센터 산하 텍사스 심장부정맥연구소, FDA 승인 신기술 무선 시스템…

오스틴, 텍사스, 2025년 7월 21일 -- 세인트 데이비드 메디컬 센터(St. David's Medical Center) 산하 텍사스 심장부정맥연구소(Texas Cardiac Arrhythmia Institute, TCAI)의 심장 전기생리학 전문의들이 심장 재동기화 치료를 제공하는 FDA 승인 신기술 무선 시스템을 미국 최초로 심부전 환자에게 이식하는 데 성공했다. 심장 재동기화 치료는 심장 수축 타이밍을 개선해 심장 박동을 정상 리듬으로 회복시키는 방법이다. 이번 첫 시술은 TCAI의 심장 전기생리학 전문의 로버트 캔비 박사(Robert Canby, M.D.)가 집도했다. TCAI의 심장 전기생리학자이자 의학총책임자인 안드레아 나탈레(Andrea Natale) 박사(F.H.R.S., F.A.C.C., F.E.S.C.)는 "이 기술은 이전까지 심장 재동기화 치료 선택지가 거의 없었던 환자들을 위한 치료 방식에 중대한 진전을 가져왔다"며, "텍사스 심장부정맥 연구소는 전 세계 환자들에게 가장 진보된 근거 기반 치료를 제공하는 데 전념하고 있으며, 캔비 박사의 리더십 덕분에 그 약속을 성공적으로 이행했다"라
- 김갑성 기자
- 2025-07-21 07:47
Tag along with Simon at CISCE: Where advanced manufactu…

BEIJING, July 18, 2025 -- This is a report from China.org.cn: At the 3rd China International Supply Chain Expo (CISCE), Canadian host Simon embarked on an immersive exploration of the advanced manufacturing zone—highlighting how global supply chains are accelerating the future of aviation, drones, and intelligent manufacturing. At the PwC booth, Simon encountered the VERTAXI eVTOL (electric vertical take-off and landing aircraft), a new-generation passenger drone designed for urban air mobility. Capable of autonomous flight and rooftop takeoff, the aircraft re
- 김갑성 기자
- 2025-07-18 22:00
Fangzhou and Novo Nordisk Signed Collaboration Memoran…

BEIJING, July 18, 2025 -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, signed a Memorandum of Understanding with Novo Nordisk, a leading global healthcare company, at the 3rd China International Supply Chain Expo in Beijing. Leveraging its AI application services, innovative treatment solutions, and convenient pharmaceutical services, Fangzhou will collaborate with Novo Nordisk on managing serious chronic diseases, such as diabetes and obesity. Fangzhou's founder, chairman, and CEO Dr. Xie F
- 김갑성 기자
- 2025-07-18 20:04
Scale Hits New High: HNC 2025 Concludes with Resounding Su…

SHANGHAI, July 18, 2025 -- Jointly organized by the China Chamber of Commerce for Import & Export of Medicines & Health Products and Sinoexpo Informa Markets, the "Healthplex Expo 2025, Natural & Nutraceutical Products China 2025" (HNC 2025) was successfully held from June 24 to 26 at the National Exhibition and Convention Center (Shanghai). The HNC 2025 once again achieved a historic breakthrough in scale, winning high praise from all participants. Held concurrently with Hi & Fi Asia-China, ProPak China & FoodPack China, and Starch Expo, the HNC built a business
- 김갑성 기자
- 2025-07-18 17:03
DNAKE Emerges as a Global Innovator in Brain-Computer Interf…

XIAMEN, China, July 18, 2025 -- Brain-Computer Interface (BCI) technology is redefining human-machine interaction by establishing direct communication between the brain and external devices. This transformative innovation is driving profound societal impact across industries: revolutionizing neurological disease treatment (e.g., epilepsy, Parkinson's, and depression), enhancing educational outcomes through improved focus, and enabling seamless industrial human-robot collaboration. With aging populations and rising neurological disorders worldwide, BCI's healthcare applications are experiencin
- 김갑성 기자
- 2025-07-18 16:19
Getinge Interim Report April-June 2025: Continuing positive tren…

GOTHENBURG, Sweden, July 18, 2025 -- "The positive start to 2025 continued in the second quarter, with stable organic growth in order intake and sales, and our margins strengthened despite strong headwinds from tariffs and negative currency effects," says Mattias Perjos, President & CEO at Getinge. The medtech company's net sales increased organically by 4.1% while order intake rose by 4.4% organically. Business area Acute Care Therapies continues to be successful in handling the increased demand for ventilators, and the order intake in ECLS consumables remains high. The
- 김갑성 기자
- 2025-07-18 14:29

이전

31 32 33 34 35 36 37 38 39 40

많이 본 기사

최근기사

2025-08-20_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 21일 01시 40분